| Western Connecticut Home Care Inc | |
| 100 Saw Mill Road, Danbury, Connecticut 6810 | |
| (203) 792-4120 | |
| Name | Western Connecticut Home Care Inc |
|---|---|
| Location | 100 Saw Mill Road, Danbury, Connecticut |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 77088 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 6470, 6482, 6488, 6611, 6752, 6755, 6776, 6778, 6783, 6784, 6794, 6798, 6801, 6804, 6810, 6811, 6812, 6820, 6824, 6825, 6829, 6840, 6850, 6851, 6852, 6853, 6854, 6855, 6856, 6875, 6877, 6880, 6883, 6890, 6896, 6897 |
| NPI Number | 1083677132 |
| Organization Name | WESTERN CONNECTICUT HOME CARE, INC |
| Address | 100 Saw Mill Rd, Danbury, CT 06810 |
| Phone Number | 203-792-4120 |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| NPI Number | 1518095801 |
| Organization Name | WESTERN CONNECTICUT HOME CARE, INC. |
| Address | 100 Saw Mill Rd, Danbury, CT 06810 |
| Phone Number | 203-792-4120 |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| Quality Rating: |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 94 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.9 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 98.4 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 78 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 92 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 95.6 | 96.4 |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 82.4 | 79.6 |
| How often patients got better at getting in and out of bed | 83.1 | 81.1 |
| How often patients got better at bathing | 86.4 | 82.3 |
| How often patients’ breathing improved | 91.4 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 92.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 77.8 | 75 |
| How often home health patients had to be admitted to the hospital | 15.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.3 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 95.3 | 94 |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
The patient survey data of Western Connecticut Home Care Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 88 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 84 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 80 | 78 |
News Archive
BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.
Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are "encouraging," but they are also "a reminder of how much work remains to be done," an Economist editorial reports.
A new technology developed by scientists at Emory University will allow researchers to more easily discover subtle and overlooked genetic variations that may have serious consequences for health and disease.
Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.
› Verified 9 days ago
Western Connecticut Home Care Inc Location: 100 Saw Mill Road, Danbury, Connecticut 6810 Ratings: Phone: (203) 792-4120 |